PerkinElmer Updates Second Quarter Outlook; To Hold Earnings Call on Tuesday, July 28, 2020

WALTHAM, Mass.–(BUSINESS WIRE)–Jul. 13, 2020– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates growth in both reported revenue and organic revenue1 of approximately 12% for the second quarter ended July 5, 2020. The strong revenue growth was driven by better-than-expected demand for PerkinElmer’s full-suite... Read more

Thermo Fisher Scientific and First Genetics JCS Partner to Develop Next-Generation Sequencing-Based Diagnostics in Russia

Thermo Fisher Scientific and First Genetics JCS Partner to Develop Next-Generation Sequencing-Based Diagnostics in Russia CARLSBAD, Calif., July 13, 2020 /PRNewswire/ — Thermo Fisher Scientific and First Genetics JCS, a manufacturer of diagnostic equipment and IVD kits intended to advance molecular genetic technologies into clinical practice, today announced a strategic partnership focused on commercializing next-generation sequencing... Read more

Thermo Fisher Scientific Provides Update to Second Quarter Outlook and Will Hold its Q2 Earnings Conference Call on Wednesday, July 22, 2020

Thermo Fisher Scientific Provides Update to Second Quarter Outlook and Will Hold its Q2 Earnings Conference Call on Wednesday, July 22, 2020 WALTHAM, Mass., July 6, 2020 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that, based on currently available information, it estimates that both reported and... Read more

New England Biolabs’ SARS-CoV-2 Rapid Colorimetric LAMP Assay Kit Enables Visual Detection of Novel Coronavirus In 30 Minutes

The research use only kit can be used as a simple alternative to RT-qPCR for SARS-CoV-2 analysis IPSWICH, MA (July 6, 2020): New England Biolabs® (NEB®) today announced the launch of the SARS-CoV-2 Rapid Colorimetric LAMP Assay Kit, a Research Use Only (RUO) product that can be used for the detection of novel coronavirus, SARS-CoV-2 RNA. The... Read more

Illumina Acquires BlueBee to Accelerate Processing, Analysis and Sharing of Next Generation Sequencing Data at Scale

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) is enhancing its capabilities to analyze and interpret the data produced by its sequencing systems with the acquisition of BlueBee, a cloud-based software company that provides genomics analysis solutions for research and clinical customers. Based in the Netherlands, BlueBee has developed a regulatory compliant, secure cloud platform that simplifies... Read more

PerkinElmer Receives FDA Emergency Use Authorization for EUROIMMUN COVID-19 RT-PCR Test

Company’s latest FDA EUA solution broadens RT-PCR and serology offerings available in the U.S. WALTHAM, Mass. – June 15, 2020 – PerkinElmer, Inc., a global leader committed to innovating for a healthier world, announced today that EUROIMMUN, a PerkinElmer Company, has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for... Read more

Zymo Research Collaborates With Companies to Support COVID-19 Testing

CALIFORNIA COMPANIES WORK TOGETHER TO MAKE NEW EUA COVID-19 TESTS AVAILABLE IRVINE, Calif., (June 11, 2020) — With the support of Zymo Research products, two California-based companies, Fulgent Genetics located in Temple City and Curative Inc. based in Menlo Park, have received Emergency Use Authorizations from the US Food and Drug Administration for their rRT-PCR tests... Read more

PCR Biosystems launches 4x RT-qPCR kit to enable ultra-sensitive, high-throughput detection of viral RNA sequences

Caption: New qPCRBIO Probe 1-Step Virus Detect. Click images to download. London, UK (11 June 2020) – PCR Biosystems, the UK-based PCR experts, today announced the launch of qPCRBIO Probe 1-Step Virus Detect, a high-concentration 4x RT-qPCR kit designed specifically for ultra-sensitive, high-throughput detection of viral RNA sequences, including SARS-CoV-2. The new kit, which marks the latest... Read more

Illumina Receives First FDA Emergency Use Authorization for a Sequencing-Based COVID-19 Diagnostic Test

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) is paving the way for large-scale, next-generation sequencing-based (NGS) COVID-19 testing. Today, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Illumina COVIDSeq™ Test, a high-throughput, sequencing-based, in vitro diagnostic (IVD) workflow enabling the detection of SARS-CoV-2. The end-to-end workflow extends the options... Read more